AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
71_CD
5_CD
Taxation_NOMZ
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
was_VBD
as_IN
follows_VPRT
:_:
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
UK_NN
879 741 618_CD
Overseas_PLACE
3,323_CD
3,296_CD
3,459_CD
4,202_CD
4,037_CD
4,077_CD
Taxes_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
142 165 147_CD
Double_RB
taxation_NOMZ
relief_NN
23_CD
29_CD
37_CD
Deferred_JJ
taxation_NOMZ
102_CD
24 53 221 160_CD
163_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
783 929 739_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
26_CD
51_CD
17_CD
Deferred_VBN
taxation_NOMZ
113 139 275 922_CD
1,017_CD
997_CD
Tax_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
1,143_CD
1,177_CD
1,160_CD
UK_NN
and_CC
overseas_PLACE
taxation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
at_PIN
current_JJ
rates_NN
on_PIN
the_DT
profits_NN
earned_VBN [WZPAST]
for_PIN
the_DT
periods_NN
covered_VBN [WZPAST]
by_PIN
the_DT
Group_NN
Financial_NN
Statements_NOMZ
._.
To_PIN
the_DT
extent_NN
that_TOBJ
dividends_NN
remitted_VBN [WZPAST]
from_PIN
overseas_PLACE
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
result_VB
in_PIN
additional_JJ
taxes_NN
,_,
appropriate_JJ
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN [STPR]
._.
No_SYNE
deferred_JJ
tax_NN
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN
unremitted_JJ
earnings_GER
of_PIN
Group_NN
companies_NN
overseas_PLACE
as_IN
these_DEMP
are_VPRT
,_,
in_PIN
the_DT
main_JJ
,_,
considered_VBN [PRIV] [PASTP]
permanently_RB
employed_VBN
in_PIN
the_DT
businesses_NOMZ
of_PIN
these_DEMO
companies_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
,_,
the_DT
taxes_NN
would_PRMD
not_XX0
be_VB
material_NN
._.
Cumulative_JJ
unremitted_JJ
earnings_GER
of_PIN
overseas_PLACE
subsidiaries_NN
and_CC
related_VBN
undertakings_GER
totalled_VBD
approximately_RB
$_$
9,381_CD
m_NN [BEMA]
at_PIN
31_CD
December_NN
2003_CD
2002_CD
$_$
9,141_CD
m._FW
Unremitted_JJ
earnings_GER
may_POMD
be_VB [BEMA]
liable_PRED
to_PIN
overseas_PLACE
taxes_NN
and_CC
or_CC
UK_NN
taxation_NOMZ
after_IN
allowing_VBG [SUAV]
for_PIN
double_JJ
taxation_NOMZ
relief_NN
if_COND
they_TPP3
were_VBD
to_TO
be_VB [PASS]
distributed_VBN
as_IN
dividends_NN
._.
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
tax_NN
on_PIN
ordinary_JJ
activities_NOMZ
:_:
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Tax_NN
credit_NN
on_PIN
exceptional_JJ
items_NN
54_CD
Includes_VPRT
deferred_JJ
tax_NN
relief_NN
of_PIN
$_$
nil_JJ
2002_CD
$_$
nil_CD
,_,
2001_CD
$_$
23m_CD
._.
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
In_PIN
certain_JJ
circumstances_NN
,_,
tax_NN
charges_NN
or_CC
credits_NN
on_PIN
currency_NN
differences_NN
on_PIN
borrowings_GER
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
tax_NN
charge_NN
on_PIN
such_JJ
currency_NN
translation_NOMZ
differences_NN
amounted_VBD
to_TO
$_$
nil_CD
in_PIN
2003_CD
2002_CD
$_$
2m_CD
,_,
2001_CD
$_$
6m_CD
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
tax_NN
credit_NN
on_PIN
other_JJ
consolidation_NOMZ
exchange_NN
adjustments_NOMZ
taken_VBN [WZPAST]
to_PIN
reserves_NN
amounted_VBD
to_TO
$_$
66m_CD
2002_CD
$_$
135m_CD
,_,
2001_CD
charge_NN
of_PIN
$_$
36m_CD
._.
Factors_NN
affecting_VBG [WZPRES]
future_JJ
tax_NN
charges_NN
As_IN
a_DT
group_NN
involved_VBN [WZPAST]
in_PIN
worldwide_JJ
operations_NOMZ
,_,
AstraZeneca_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
several_QUAN
factors_NN
that_TSUB
may_POMD
affect_VB
future_JJ
tax_NN
charges_NN
,_,
principally_RB
the_DT
levels_NN
and_PHC
mix_NN
of_PIN
profitability_NOMZ
in_PIN
different_JJ
jurisdictions_NOMZ
,_,
transfer_NN
pricing_GER
policies_NN
and_PHC
tax_NN
levels_NN
imposed_VBN
._.
In_PIN
2003_CD
,_,
a_DT
settlement_NOMZ
was_VBD [PASS]
negotiated_VBN
with_PIN
the_DT
UK_NN
and_PHC
US_FPP1
governments_NOMZ
covering_VBG [WZPRES]
all_QUAN
liabilities_NOMZ
potentially_RB
arising_VBG
from_PIN
transfer_NN
pricing_GER
in_PIN
respect_NN
of_PIN
ex-Zeneca_NN
products_NN
for_PIN
the_DT
years_NN
1987_CD
to_PIN
2001_CD
._.
The_DT
settlement_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN
in_PIN
previous_JJ
years_NN
and_CC
had_VBD
no_SYNE
impact_NN
on_PIN
the_DT
2003_CD
tax_NN
charge_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
72_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
5_CD
Taxation_NOMZ
continued_VBD
Tax_NN
reconciliation_NOMZ
to_PIN
UK_NN
statutory_JJ
rate_NN
The_DT
table_NN
shown_VBN [PRIV]
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
to_PIN
the_DT
Groups_NN
current_JJ
tax_NN
charge_NN
on_PIN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
._.
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
4,202_CD
4,037_CD
4,077_CD
Notional_NN
taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
30_CD
%_NN
for_PIN
2002_CD
,_,
30_CD
%_NN
for_PIN
2001_CD
1,261_CD
1,211_CD
1,223_CD
Differences_NN
in_PIN
effective_JJ
overseas_PLACE
tax_NN
rates_NN
159 141 108_CD
Capital_NN
allowances_NN
tax_NN
reliefs_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
291 291 401_CD
Untaxed_JJ
reserves_NN
51_CD
75_CD
11_CD
Other_JJ
timing_NN
differences_NN
168_CD
35_CD
88_CD
Items_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
80_CD
49_CD
48_CD
Items_NN
not_XX0
chargeable_JJ
for_PIN
tax_NN
purposes_NN
88_CD
110_CD
58_CD
Adjustments_NOMZ
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
26_CD
51_CD
17_CD
Exceptional_JJ
items_NN
105_CD
28_CD
Current_JJ
tax_NN
charge_NN
for_PIN
the_DT
year_NN
928_CD
1,014_CD
832_CD
Balance_NN
sheet_NN
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
taxation_NOMZ
liability_NOMZ
asset_NN
movement_NOMZ
At_PIN
beginning_GER
of_PIN
year_NN
359_CD
212_CD
96_CD
Profit_NN
and_PHC
loss_NN
account_NN
215 163 328_CD
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
155_CD
19_CD
Disposal_NN
of_PIN
subsidiary_NN
undertakings_GER
13_CD
Exchange_NN
132_CD
139_CD
39_CD
At_PIN
end_NN
of_PIN
year_NN
693 359 212_CD
Debtors_NN
amount_NN
due_JJ
within_PIN
one_CD
year_NN
Note_NN
13 732 625 550_CD
Debtors_NN
amount_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Note_NN
13 165 226 146_CD
Provisions_NN
Note_VPRT [PRIV]
19_CD
1,590_CD
1,210_CD
908 693 359 212_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
73_CD
5_CD
Taxation_NOMZ
continued_VBD
Deferred_JJ
taxation_NOMZ
The_DT
amounts_NN
of_PIN
deferred_VBN
taxation_NOMZ
accounted_VBD
for_PIN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
,_,
before_IN
netting_VBG
off_PIN
of_PIN
balances_NN
within_PIN
countries_NN
,_,
comprised_VBD
the_DT
following_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
:_:
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD [PASS]
Deferred_VBN
tax_NN
liabilities_NOMZ
UK_NN
fixed_VBN
assets_NN
501_CD
429_CD
Non-UK_JJ
fixed_JJ
assets_NN
735_CD
570_CD
Interest_NN
accruals_VPRT
18_CD
13_CD
Untaxed_JJ
reserves_NN
137_CD
86_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
86_CD
46_CD
Other_JJ
175_CD
53_CD
1,652_CD
1,197_CD
Deferred_JJ
tax_NN
assets_NN
Intercompany_NN
inventory_NN
transfers_NN
527_CD
496_CD
Non-UK_JJ
fixed_JJ
assets_NN
28_CD
Merger_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
charges_NN
16_CD
Accrued_VBN
expenses_NN
238_CD
243_CD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
55_CD
26_CD
Other_JJ
111 57 959 838_CD
Deferred_JJ
tax_NN
liability_NOMZ
net_JJ
693_CD
359_CD
No_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
,_,
in_PIN
accordance_NN
with_PIN
FRS19_CD
,_,
for_PIN
rolled_VBN
over_IN
gains_NN
amounting_VBG [WZPRES]
to_TO
$_$
140m_CD
2002_CD
$_$
126m_CD
,_,
2001_CD
$_$
75m_CD
._.
